The global neurological biomarkers market is expected to witness a rapid growth with the prevailing neurological disorder cases all over the world. A major percentage of world population is affected by neurological disorders, this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual.
There are different variations of biomarkers in the market on the basis of type, application and end users. Based on application, the global neurological biomarkers market is segmented into Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Depression, Schizophrenia, Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease. With respect to type, biomarkers are classified into Imaging biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers. Among these, genomics biomarker is anticipated to hold a larger share in the overall market as compared to the others. On the basis of end users, the neurological biomarkers market is categorized into hospitals and research institutes and diagnostic centers.
The report presented here is a complete evaluation of the global neurological biomarkers market with large focus on market dynamics that also includes the market drivers, restraints, and trends and opportunities. It also offers geographical and other segmentation studies of the market.
The market for neurological biomarkers is anticipated to remain active with the urge in research initiatives that are taking place. The demand for validating and identifying biomarkers from large population is huge. The research process is being conducted with the help of this method, thus increasing the expectancy of accelerating the neurological biomarkers market growth in the future years.
With the introduction of new neurological biomarkers, the neuropathologists will have to play a crucial role in selection and characterization of suitable treatment strategies. Furthermore, with the advent of personalized and telehealth medication, single-cell biosensors are emerging. These single-cell biosensors can help to integrate molecular and clinical information on a large scale.
Biomarkers are also used for those patients who suffer from traumatic brain injury, subarachnoid hemorrhage, intracerebral hemorrhage, and acute ischemic stroke. The recovery of such crucial and neurocritical diseases is dependent on the mitigation of the patient. In these kind of situations, there may be a delay in conducting image studies or proper examination of the patient because of the complexities involved. This flaw has promoted the use of biomarkers in the market. As the demand for neurological concern is on the rise, so is the market for neurological biomarkers is also on the rise.
The global neurological biomarkers market is classified into the regions of Middle East and Africa, Asia Pacific, Latin America, North America and Europe. . Owing to the presence of many noteworthy players, North America is projected to be witnessing a larger share of the overall market as compared to the other regions. A number of research and development projects are carried out in various areas of North America and academic universities have also received the fund provided by the government in order to undertake research.
Apart from North America, the region anticipated exhibit a faster growth is Asia Pacific. This is because of the large population base, and the increasing incidental rates of neurological abnormalities. Apart from that, factors like rising number if geriatric population and the entry of new players into the market may also add pace to the overall market growth of the Asia Pacific region in the years to come.
Major companies in the neurological biomarkers market are Athena Diagnostics, Myriad RBM, AbaStar MDx, QIAGEN, and Thermo Fisher Scientific.